LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Avatud

SektorTervishoid

20.54 -4.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.7

Max

23.4

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -129M
Aktsiakasum	-0.73
Töötajad	503
EBITDA	8.9M -125M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+57.84% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. mai 2026

Turustatistika
By TradingEconomics
Turukapital	87M 3.3B
Eelmine avamishind	25.05
Eelmine sulgemishind	20.54

Uudiste sentiment

By Acuity

29%

71%

69 / 350 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. märts 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Infosys Agrees to Acquire Stratus

25. märts 2026, 23:58 UTC

Tulu

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25. märts 2026, 23:58 UTC

Tulu

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25. märts 2026, 23:41 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25. märts 2026, 23:41 UTC

Tulu

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25. märts 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Declines on Possible Technical Correction -- Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25. märts 2026, 21:58 UTC

Market Talk

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25. märts 2026, 21:37 UTC

Market Talk

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25. märts 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25. märts 2026, 21:13 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. märts 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

25. märts 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25. märts 2026, 20:31 UTC

Tulu

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

57.84% tõus

12 kuu keskmine prognoos

Keskmine 33.1 USD 57.84%

Kõrge 40 USD

Madal 25 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

69 / 350 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.